Introduction: For patients with esophageal cancer undergoing neoadjuvant chemoradiation (CRT) followed by surgical resection, complete histopathologic response (pCR) is associated with favorable overall survival (OS). The aim of this study was to evaluate the correlation between
Introduction
For locally advanced esophageal cancer, prospective clinical trials have demonstrated that neoadjuvant chemoradiation (CRT) before surgery provides a significant survival advantage compared with surgery alone. [1] [2] [3] Patients who have a complete pathologic response (pCR) to neoadjuvant treatment have improved overall survival (OS) compared with patients who do not have a pCR. 4, 5 It is plausible that some patients who achieve a pCR have been cured by CRT alone and may not derive additional benefit from esophagectomy. However, noninvasive assessments of pCR have not yet been clearly established, which limits the ability to investigate the efficacy of nonoperative management of esophageal cancer. Conversely, patients with an incomplete response to CRT are less likely to be cured without esophagectomy and could benefit from alterations in neoadjuvant therapeutic strategy. Thus, an accurate noninvasive assessment of response to neoadjuvant CRT could be useful in directing individualized treatment strategies, specifically, in possible selective omission of planned surgery in a subset of patients achieving a complete response.
Endoscopic ultrasonography, esophagogastroscopy, and computed tomography (CT) have been used to assess response to therapy. However, differentiating the responsive versus the active disease can be difficult with these imaging modalities. 6 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) (FDG PET) imaging has a well-established value in the staging of esophageal cancer at initial diagnosis 7 and for evaluation of nodal disease and distant metastasis after neoadjuvant therapy. 8 PET and CT (PET/CT) characterization of local disease in esophageal cancer remains controversial; however, several investigators have reported that PET better differentiates residual primary tumor from posttherapy scar after CRT. 9, 10 Currently, interest exists in the potential predictive value of FDG PET imaging and its accuracy in the assessment of treatment response to neoadjuvant therapy. Studies thus far have presented contradictory findings regarding the prognostic value of FDG PET. [11] [12] [13] Furthermore, the ideal parameters for evaluating FDG PET response have not been clearly defined. Prior studies [11] [12] [13] have used maximum standard uptake value (SUV max ) and change in standard uptake value to predict response, whereas more recent studies have suggested that standard uptake ratio (SUR) may be superior to standard uptake value (SUV) in the assessment of treatment response.
14 Therefore, use of FDG PET to direct therapeutic decision making for local disease remains controversial but continues to be an important area of research. The goal of the present study was to further evaluate the utility of FDG PET imaging in predicting local tumor response to neoadjuvant CRT and associated OS.
Materials and Methods

Patients
This retrospective study evaluated patients with nonmetastatic esophageal cancer treated with neoadjuvant CRT and resection at a single institution from January 2007 through June 2012. The Mayo Clinic Institutional Review Board approved this study. The Mayo Clinic Cancer Registry was queried for data regarding all patients with esophageal cancer who were treated with neoadjuvant CRT followed by resection at our institution. Patients who did not undergo an operation were excluded from analysis, as were patients who did not receive both preneoadjuvant CRT and postneoadjuvant CRT FDG PET/ CT assessment. In addition, patients with inoperable or metastatic disease were excluded from the analysis.
Staging
The disease of the patients was clinically staged according to the American Joint Committee on Cancer, seventh edition, guidelines before administration of neoadjuvant CRT. Pretreatment staging evaluation included endoscopy; contrast medium-enhanced spiral CT of the chest, abdomen, and pelvis; endoscopic ultrasonography; and FDG PET/CT. A pretreatment staging laparoscopy was performed only if there was suspicion of peritoneal dissemination of disease. After completion of CRT, restaging typically consisted of FGD PET/CT only. Endoscopy and/or dedicated CT were typically performed only if the FDG PET/CT findings were suggestive of unresectable and/or metastatic disease.
Treatment
All patients were treated with neoadjuvant concurrent external beam radiation and chemotherapy at our institution. The median radiation dose was 50.4 Gy (interquartile range [IQR] 50.4-50.4, range 27.0-50.4). After completion of neoadjuvant CRT, all patients underwent esophagectomy or esophagogastrectomy and lymph node dissection. All pathologic specimens were reviewed at a single institution (Mayo Clinic). pCR was defined as absence of viable tumor in the primary site and negative lymph nodes (ypT0N0).
PET/CT Image Acquisition
PET/CT was performed on Discovery RX or 690 three-dimensional dedicated PET/CT scanners (GE Health Care, Pittsburgh, PA) according to the institutional standard clinical protocol. All patients underwent baseline FDG PET/CT before initiation of neoadjuvant therapy. Posttreatment FDG PET/CT was typically performed 4 to 6 weeks after completion of CRT.
PET/CT studies were completed after a standard 6-hour fast. The blood glucose level at injection was 150 mg/dL or less and the dose of FDG was approximately 15 mCi in all patients. No intravenous or oral contrast medium was used. Most patients had a reported uptake time of 60 minutes. Imaging of the patients was performed with their arms up (unless not tolerated by the patient) and from orbits through upper thighs (three-dimensional, 128 Â 128 matrix, 3 minutes per bed). PET images were reconstructed with a threedimensional ordered subsets expectation maximization algorithm (28 subsets and two iterations). Low-dose, unenhanced helical CT images were obtained for attenuation correction and anatomical localization (detector row configuration 16 Â 0.625 mm, pitch 1.75; gantry rotation time 0.5 second, slice thickness 3.75 mm, and 140 kVP and mAs range 60-120 with automatic current modulation). The pretreatment examinations for 29 patients were completed at an outside facility using a similar technique and uptake time. All examinations after CRT were completed at our institution.
Measurements of Metabolic FDG PET Parameters
All pretreatment and posttreatment FDG PET/CT images were retrospectively reviewed on a dedicated GE Advantage workstation using Volume Viewer software (GE Healthcare) by a sole nuclear medicine radiologist (E. M. M.) to whom treatment outcomes were masked. The three-dimensional volumes of interest were drawn at the primary site of highest-intensity uptake in the esophagus and proximal stomach on the pretreatment examination and corresponding location on the posttreatment examination to obtain pretreatment and posttreatment SUV max values. FDG PET complete response was defined as normalization of tumor FDG activity to hepatic standard uptake value mean (SUV mean ) or blood pool SUV mean in the clinical setting of underlying hepatic fatty infiltration. For SUR analysis, volumes of interest were placed in the right hepatic lobe (3 cm in diameter) and the right atrium or blood pool (1 cm in diameter) on the pretreatment and posttreatment examinations. SUR values were computed as the ratios of tumor SUV max to blood pool and liver SUV mean (SUR-BP and SUR-L, respectively).
Statistical Analysis
Analyses were performed with statistical software (JMP version 10.0; SAS Institute, Inc., Cary, NC). OS was measured from the date of treatment initiation to the date of death or last documented follow-up, and it was estimated with the Kaplan-Meier method. Univariate analysis was used to identify potential variables associated with complete FDG PET response and pCR using univariate logistic regression analysis and smoothing spline theory. A p value less than 0.05 was considered statistically significant. Investigated variables included patient sex, histologic findings, radiation therapy dose, tumor size on endoscopy, tumor location, and T stage, as well as SUV and SUR PET parameters. Positive and negative predictive values for each threshold value were calculated using standard formulas.
Results
Patient and Treatment Characteristics
A total of 193 patients were identified. Patient and treatment parameters are summarized in Table 1 . More than 80% of the study patients were male, and most of the treated cancers were gastroesophageal junction adenocarcinoma stage T3 or higher with nodal involvement. Most patients had stage III (59.8%) or stage II (37.1%) disease; two patients (1%) with stage I disease and four patients (2.1%) with stage IV disease were also 
FDG PET Parameters
The values of investigated FDG PET parameters are summarized in Table 2 . The average time from completion of CRT to posttreatment PET/CT imaging was 5 weeks (IQR 4.3-5.9, range 1.6-10.0 weeks). The average time from PET/CT imaging to surgery was 9.3 days (IQR 1-14, range 1-65 days).
Correlation between FDG PET Parameters and Tumor Response
The rates of FDG PET complete response and pCR were 27% and 34%, respectively. No significant association was found between any of the investigated clinical parameters-which included histologic subtype, radiation dose, tumor size, tumor location, and T stage-and either FDG PET complete response or pCR (Tables 3 and 4) . The rates of pCR in patients with and without FDG PET complete response were 42% and 31%, respectively (p ¼ 0.17). The positive and negative predictive values of FDG PET complete response in predicting pCR were 41.5% and 69.1%, respectively. No association was observed between change in SUV max (DSUV max ), change in SUR-BP, or change in SUR-L and pCR (Table 3) . Threshold change values of a 25%, 30%, and 35% decrease in SUV max were not associated with pCR. In addition, pretreatment FDG activity with any of the FDG PET parameters did not correlate with pCR.
Correlation between FDG PET Parameters and OS
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Discussion
In the present study, we investigated the prognostic value of post-CRT FDG PET imaging of patients with esophageal carcinoma who completed trimodality therapy. Consistent with prior reports, 4, 5, 15 pCR was associated with improved OS. However, FDG SUV and SUR metrics for local disease did not significantly correlate with pCR or OS.
Thus far, the literature has reported conflicting results regarding the utility of FDG PET imaging in predicting histopathologic response of the primary tumor to neoadjuvant treatment. A number of the studies were generated with smaller cohorts of patients, which may contribute to the variability of reported results. [16] [17] [18] [19] Furthermore, the ideal PET parameters used to assess response have not been clearly established, and the lack of a standardized approach to data analysis provides an additional confounding factor.
Our results are similar to those reported by Jayachandran et al. 19 and Schmidt et al. 18 Jayachandran et al. correlated pre-and post-CRT metabolic tumor volume, metabolic tumor volume ratio, and SUV max in a cohort of 37 patients with T1 to T4 esophageal carcinoma. They did not identify a significant correlation between histopathologic response and any of the investigated PET parameters, although patients with a strong reduction in metabolic tumor volume after definitive CRT had improved OS. Of note, only 57% of patients included in that study were able to proceed to resection. Schmidt et al. evaluated SUV max and percent change in SUV max in a cohort of 55 patients with locally advanced esophageal cancer (T3-T4). The investigators used receiver operating characteristic curves in an attempt to identify optimum cutoff values for percent reduction of SUV max . All patients included in their study proceeded to resection and their disease was graded on the basis of histopathologic response. Sensitivity was poor for both adenocarcinoma and squamous histologic types, and PET, positron emission tomography; CI, confidence interval; DSUR, decrease in standard uptake ratio; DSUV max , decrease in maximal standard uptake value; SUR, standard uptake ratio; SUV max , maximal standard uptake value. neither baseline nor preoperative SUV max correlated significantly with histopathologic response or OS. In contrast, the results reported by Cerfolio et al. 20 support the use of SUV max as a prognostic variable in pCR prediction at the primary tumor. They investigated SUV max and relative change in SUV max in a series of 86 patients. Cerfolio et al. reported that histopathologic response was optimally predicted by a threshold value of more than a 64% decrease in baseline SUV max , but they did not report data regarding OS or disease-free survival. They suggested that the variability in results obtained at independent institutions may be most attributable to differences in the administration of injected FDG. Although this factor continues to be a valid concern, it has become less of an issue in recent years as imaging centers have adopted more-standardized FDG PET protocols.
Our results are distinctive in that they represent data from one of the largest retrospective cohorts of such patients treated at a single institution. Furthermore, we expanded our analysis to include a broad range of FDG PET parameters and normalization techniques that have not been previously evaluated in a similar cohort of patients. Most prior studies have used SUV max and DSUV max as primary assessment values. However, recent reports have suggested that SUR may represent a more accurate and reliable parameter for response assessment in some instances. 14, 21 The SUR value incorporates normalization to anatomical reference regions that represent baseline metabolic activity in individual patients. Thus, use of SUR has the potential to address some of the inherent variability of SUV methodology. Unfortunately, neither SUR nor change in SUR was of any additional prognostic utility in the present series of patients. These results remained equivalent whether SUR was normalized to metabolic activity of the mediastinal blood pool or liver, which suggests that the results were not influenced by normalization parameters.
The poor correlation between FDG PET response and pCR may be partially explained by the use of radiation in neoadjuvant therapy. Radiation induces an inflammatory reaction within the treatment field. The inflammatory response can lead to increased metabolic activity and FDG-avidity for PET/CT imaging performed soon after completion of radiation therapy, which has the potential to confound measured FDG PET parameters at the primary tumor site and decrease specificity for residual disease after neoadjuvant CRT. This concern can be partially addressed by delaying the preoperative imaging until radiation-induced inflammation has resolved, but timing is constrained by the need to avoid detrimental delays, allowing for possible disease progression before definitive resection. In contrast, some patients have a complete response evident on FDG PET images but are found to have residual disease after resection. Some investigators have hypothesized that this finding may be due to a paradoxical inhibition of FDG uptake in response to CRT 18, 22 in a manner similar to the reported inhibition of FDG uptake in transiently ischemic cardiac tissue. 23 The hypothesis remains speculative, but it appears plausible and merits further research. Of note, investigators who have used neoadjuvant chemotherapy alone have reported more consistent correlation between PET response and histopathologic response. 11, 12 This finding lends further support to the hypothesis that radiation may be a primary confounding factor in the interpretation of FDG PET parameters in the clinical setting of trimodality therapy. Alternatively, smallvolume residual disease at histopathologic examination of the surgical specimen may be below the resolution of the post-CRT FDG PET/CT and lead to a false-negative PET result. This is a retrospective study and thus is subject to the inherent limitations and potential biases. All FDG PET/ CT scans were interpreted by a single nuclear medicine physician blinded to treatment outcomes, which is both a strength (improved standardization and reduced interobserver variability) and weakness of the study. Its application is limited to patients undergoing neoadjuvant CRT and does not speak to the prognostic value of FDG PET imaging in the assessment of response to chemotherapy alone. Most patients in our study underwent FDG PET and an operation within 6 weeks of completion of neoadjuvant CRT; therefore, we are unable to assess whether FDG PET may have greater utility in patients in whom assessment is delayed until 10 to 14 weeks after CRT. This strategy is being assessed in the ongoing trial of the operation-as-needed approach in esophageal cancer (preSANO trial). 24 The vast majority (85%) of patients in our cohort had adenocarcinoma histologic findings. Thus, we are unable to firmly assess the utility of FDG PET specifically in patients with squamous cell carcinoma histologic findings, for whom selective omission of surgery may be more relevant. 25, 26 Although FDG PET/CT alone was not able to predict local tumor response in our cohort, it is possible that FDG PET/CT combined with other investigative techniques, such as endoscopy, biopsy, testing for novel blood biomarkers, and/or novel imaging modalities, may have utility in predicting local tumor response. Further research in this regard is warranted.
In conclusion, our results do not support the use of FDG PET for determining local response of esophageal carcinoma after neoadjuvant CRT. However, posttreatment FDG PET continues to be important in assessment for distant metastatic disease development. Further research is needed to determine whether newer imaging techniques, such as novel PET radiotracers and multiparametric magnetic resonance imaging, have utility in assessing local tumor response after neoadjuvant CRT.
